Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017459 · ClinicalTrials.gov registry record · Phase 3
Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00017459: Completed Phase 3 study, sponsored by Sanofi.
NCT00017459 is a Phase 3 study that has completed, run by Sanofi. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017459, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin and vinorelbine are more effective with or without tirapazamine in treating non-small cell lung cancer PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus vinorelbine with or without tirapazamine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG vinorelbine tartrate
- DRUG tirapazamine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2004-02 |
| Phase | Phase 3 |
What the finished NCT00017459 record still lists
NCT00017459 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00017459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00017459 about?
NCT00017459 is a clinical study titled "Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin and vinorelbine are more effective with or without tirapazamine in treating non-small cell lung cancer PURPOSE: Randomized phase III trial to comp...
What is the current status of trial NCT00017459?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-07. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00017459?
The interventions under investigation include: cisplatin (DRUG), vinorelbine tartrate (DRUG), tirapazamine (DRUG).
Who is sponsoring clinical trial NCT00017459?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia